BJL
SRPT icon

Brighton Jones LLC’s Sarepta Therapeutics SRPT Stock Holding History

Brighton Jones LLC’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$350K Sell
19,491
-13,502
-41% -$255K 0.01% 969
2026
Q1 		$718K Buy
+32,993
New +$639K 0.02% 559
2018
Q3 		– Sell
-4,685
Closed -$619K – 312
2018
Q2 		$619K Buy
4,685
+8
+0.2% +$754 0.08% 145
2018
Q1 		$347K Buy
4,677
+16
+0.3% +$1.07K 0.05% 196
2017
Q4 		$259K Hold
4,661
– – 0.03% 238
2017
Q3 		$211K Buy
+4,661
New +$186K 0.03% 264

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Brighton Jones LLC's SRPT Position: Q2 2026 in Review

Brighton Jones LLC reduced its Sarepta Therapeutics (SRPT) stake by 41% in Q2 2026, selling an estimated $255K and leaving 19,491 shares worth $350K. The position accounts for 0.01% of the portfolio, ranked #969.

Brighton Jones LLC first reported a position in SRPT in Q3 2017 and has held it in 6 quarters since. The position peaked at $718K in Q1 2026. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Brighton Jones LLC held 19,491 shares of Sarepta Therapeutics worth $350K as of Q2 2026.
  • Brighton Jones LLC sold 13,502 Sarepta Therapeutics shares in Q2 2026, an estimated $255K.
  • Sarepta Therapeutics made up 0.01% of Brighton Jones LLC's portfolio in Q2 2026, its #969 holding.
  • Brighton Jones LLC first reported a position in Sarepta Therapeutics in Q3 2017 and has held it in 6 quarters since.
  • Brighton Jones LLC's Sarepta Therapeutics position peaked at $718K in Q1 2026.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Brighton Jones LLC's 13F filing for Q2 2026, filed 11 Aug 2026.